Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction

Hovav Nechushtan, Dien Pham, Yu Zhang, Daniel Morgensztern, Kyung H. Yi, Seung-Uon Shin, Howard J. Federoff, William J. Bowers, Khaled A. Tolba, Joseph D Rosenblatt

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment of cancer with cytotoxic agents may induce lymphopenia. Adoptively transferred T cells have been reported to display enhanced anti-tumor efficacy in the lymphopenic setting. We reasoned that the anti-tumor effects of adoptively transferred cells in the lymphopenic host could be further augmented through local provision of an innate stimulus in the tumor bed. Utilizing a model in which mice were irradiated to induce lymphopenia, with limited shielding to allow tumor growth, we demonstrate that "triple" therapy consisting of radiation-induced lymphopenia, adoptive transfer of naïve CD8+ T cells, and intra-tumoral HSV amplicon injection resulted in reduced tumor growth compared to the combination of any two of the aforementioned interventions. To gain insight into the mechanism underlying this effect we studied the effects of HSV amplicon transduction into tumors on cytokine expression and on anti-tumor specific T cells. HSV amplicon transduction specifically induced several cytokine mRNAs including IFN-γ, and IP-10. Adoptively transferred transgenic OT-1 T cells directed against Ovalbumin were more effective against Ovalbumin-expressing tumors when combined with intra-tumoral HSV amplicon injections in the lymphopenic host. Following intra-tumoral HSV-amplicon injections, anti-tumor T cells secreted higher levels of interferon-γ in response to in-vitro re-stimulation with tumor cells, implying that HSV amplicon injection provided a strong signal for T cell activation. Combining adoptive transfer of naïve T cells in the lymphopenic setting with local T cell stimulation may facilitate expansion and activation of anti-tumor T cell populations in vivo, resulting in enhanced anti-tumor responses without the need to resort to prolonged in vitro T cell culture and/or manipulation.

Original languageEnglish
Pages (from-to)663-675
Number of pages13
JournalCancer Immunology, Immunotherapy
Volume57
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

T-Lymphocytes
Neoplasms
Lymphopenia
Injections
Adoptive Transfer
Ovalbumin
Cytokines
Cytotoxins
Growth
Interferons
Radiotherapy
Cell Culture Techniques
Messenger RNA
Population

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. / Nechushtan, Hovav; Pham, Dien; Zhang, Yu; Morgensztern, Daniel; Yi, Kyung H.; Shin, Seung-Uon; Federoff, Howard J.; Bowers, William J.; Tolba, Khaled A.; Rosenblatt, Joseph D.

In: Cancer Immunology, Immunotherapy, Vol. 57, No. 5, 01.05.2008, p. 663-675.

Research output: Contribution to journalArticle

Nechushtan, Hovav ; Pham, Dien ; Zhang, Yu ; Morgensztern, Daniel ; Yi, Kyung H. ; Shin, Seung-Uon ; Federoff, Howard J. ; Bowers, William J. ; Tolba, Khaled A. ; Rosenblatt, Joseph D. / Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. In: Cancer Immunology, Immunotherapy. 2008 ; Vol. 57, No. 5. pp. 663-675.
@article{58af04928bd645b89e74f1574cf632b9,
title = "Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction",
abstract = "Treatment of cancer with cytotoxic agents may induce lymphopenia. Adoptively transferred T cells have been reported to display enhanced anti-tumor efficacy in the lymphopenic setting. We reasoned that the anti-tumor effects of adoptively transferred cells in the lymphopenic host could be further augmented through local provision of an innate stimulus in the tumor bed. Utilizing a model in which mice were irradiated to induce lymphopenia, with limited shielding to allow tumor growth, we demonstrate that {"}triple{"} therapy consisting of radiation-induced lymphopenia, adoptive transfer of na{\"i}ve CD8+ T cells, and intra-tumoral HSV amplicon injection resulted in reduced tumor growth compared to the combination of any two of the aforementioned interventions. To gain insight into the mechanism underlying this effect we studied the effects of HSV amplicon transduction into tumors on cytokine expression and on anti-tumor specific T cells. HSV amplicon transduction specifically induced several cytokine mRNAs including IFN-γ, and IP-10. Adoptively transferred transgenic OT-1 T cells directed against Ovalbumin were more effective against Ovalbumin-expressing tumors when combined with intra-tumoral HSV amplicon injections in the lymphopenic host. Following intra-tumoral HSV-amplicon injections, anti-tumor T cells secreted higher levels of interferon-γ in response to in-vitro re-stimulation with tumor cells, implying that HSV amplicon injection provided a strong signal for T cell activation. Combining adoptive transfer of na{\"i}ve T cells in the lymphopenic setting with local T cell stimulation may facilitate expansion and activation of anti-tumor T cell populations in vivo, resulting in enhanced anti-tumor responses without the need to resort to prolonged in vitro T cell culture and/or manipulation.",
author = "Hovav Nechushtan and Dien Pham and Yu Zhang and Daniel Morgensztern and Yi, {Kyung H.} and Seung-Uon Shin and Federoff, {Howard J.} and Bowers, {William J.} and Tolba, {Khaled A.} and Rosenblatt, {Joseph D}",
year = "2008",
month = "5",
day = "1",
doi = "10.1007/s00262-007-0405-1",
language = "English",
volume = "57",
pages = "663--675",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

TY - JOUR

T1 - Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction

AU - Nechushtan, Hovav

AU - Pham, Dien

AU - Zhang, Yu

AU - Morgensztern, Daniel

AU - Yi, Kyung H.

AU - Shin, Seung-Uon

AU - Federoff, Howard J.

AU - Bowers, William J.

AU - Tolba, Khaled A.

AU - Rosenblatt, Joseph D

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Treatment of cancer with cytotoxic agents may induce lymphopenia. Adoptively transferred T cells have been reported to display enhanced anti-tumor efficacy in the lymphopenic setting. We reasoned that the anti-tumor effects of adoptively transferred cells in the lymphopenic host could be further augmented through local provision of an innate stimulus in the tumor bed. Utilizing a model in which mice were irradiated to induce lymphopenia, with limited shielding to allow tumor growth, we demonstrate that "triple" therapy consisting of radiation-induced lymphopenia, adoptive transfer of naïve CD8+ T cells, and intra-tumoral HSV amplicon injection resulted in reduced tumor growth compared to the combination of any two of the aforementioned interventions. To gain insight into the mechanism underlying this effect we studied the effects of HSV amplicon transduction into tumors on cytokine expression and on anti-tumor specific T cells. HSV amplicon transduction specifically induced several cytokine mRNAs including IFN-γ, and IP-10. Adoptively transferred transgenic OT-1 T cells directed against Ovalbumin were more effective against Ovalbumin-expressing tumors when combined with intra-tumoral HSV amplicon injections in the lymphopenic host. Following intra-tumoral HSV-amplicon injections, anti-tumor T cells secreted higher levels of interferon-γ in response to in-vitro re-stimulation with tumor cells, implying that HSV amplicon injection provided a strong signal for T cell activation. Combining adoptive transfer of naïve T cells in the lymphopenic setting with local T cell stimulation may facilitate expansion and activation of anti-tumor T cell populations in vivo, resulting in enhanced anti-tumor responses without the need to resort to prolonged in vitro T cell culture and/or manipulation.

AB - Treatment of cancer with cytotoxic agents may induce lymphopenia. Adoptively transferred T cells have been reported to display enhanced anti-tumor efficacy in the lymphopenic setting. We reasoned that the anti-tumor effects of adoptively transferred cells in the lymphopenic host could be further augmented through local provision of an innate stimulus in the tumor bed. Utilizing a model in which mice were irradiated to induce lymphopenia, with limited shielding to allow tumor growth, we demonstrate that "triple" therapy consisting of radiation-induced lymphopenia, adoptive transfer of naïve CD8+ T cells, and intra-tumoral HSV amplicon injection resulted in reduced tumor growth compared to the combination of any two of the aforementioned interventions. To gain insight into the mechanism underlying this effect we studied the effects of HSV amplicon transduction into tumors on cytokine expression and on anti-tumor specific T cells. HSV amplicon transduction specifically induced several cytokine mRNAs including IFN-γ, and IP-10. Adoptively transferred transgenic OT-1 T cells directed against Ovalbumin were more effective against Ovalbumin-expressing tumors when combined with intra-tumoral HSV amplicon injections in the lymphopenic host. Following intra-tumoral HSV-amplicon injections, anti-tumor T cells secreted higher levels of interferon-γ in response to in-vitro re-stimulation with tumor cells, implying that HSV amplicon injection provided a strong signal for T cell activation. Combining adoptive transfer of naïve T cells in the lymphopenic setting with local T cell stimulation may facilitate expansion and activation of anti-tumor T cell populations in vivo, resulting in enhanced anti-tumor responses without the need to resort to prolonged in vitro T cell culture and/or manipulation.

UR - http://www.scopus.com/inward/record.url?scp=43149098300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149098300&partnerID=8YFLogxK

U2 - 10.1007/s00262-007-0405-1

DO - 10.1007/s00262-007-0405-1

M3 - Article

C2 - 17952436

AN - SCOPUS:43149098300

VL - 57

SP - 663

EP - 675

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 5

ER -